PhaseV Raises $50M Series A to Accelerate AI Integration in Clinical Development
PhaseV, a company specializing in AI and machine learning applied to clinical development, has secured $50 million in a Series A funding round. The investment was co-led by Accel and Insight Partners, with continued support from existing investors Viola Ventures, EXOR, and LionBird. This latest round raises PhaseV's total funding to $65 million.
According to Raviv Pryluk, PhD, CEO and Co-Founder of PhaseV, the pharmaceutical industry faces increasing pressure to improve the speed, cost-efficiency, and success rates of clinical trials. This capital injection will help PhaseV expand its AI platform, enabling more pharmaceutical companies, biotech firms, and contract research organizations (CROs) to adopt advanced AI and machine learning solutions for clinical development.
Expanding AI-Driven Solutions for Clinical Trials
PhaseV's platform supports a comprehensive approach to clinical development, from trial design through execution. It currently serves over 30 global pharmaceutical companies and spans more than 20 therapeutic areas, including neurology, oncology, gastrointestinal disorders, immunology, metabolic diseases, and rare diseases.
The platform integrates a wide range of high-quality patient-level data, clinical trial results, real-world evidence, and peer-reviewed insights. This integration has helped reduce trial costs by 50%, decrease enrollment size and trial duration by 40%, and increase the likelihood of trial success by over 30%. One client reduced time-to-market by 15 months through PhaseV’s solutions.
Core Features of PhaseV’s AI Platform
- Trial Optimizer: Enhances trial design using Bayesian, adaptive, and fixed trial methods.
- Causal ML: Detects heterogeneous treatment effects to identify promising subpopulations and endpoints.
- Causal Disease Modeling: Supports R&D and lifecycle management decisions.
- Clinical Operations: Provides AI-driven site selection, performance analytics, real-time monitoring, and virtual control arm integration.
Industry Recognition and Partnerships
Matt Robinson, Partner at Accel, highlighted PhaseV’s strong partnerships with leading pharma companies as a key factor in their market traction. Insight Partners’ Managing Director Dylan Morris emphasized the company’s potential to transform clinical trial design and accelerate drug development.
Stu Bailey, D.Phil., SVP Head of Clinical Measurement Sciences at EMD Serono, shared that PhaseV’s causal machine learning helped identify clinically meaningful subgroups in their trials, adding tangible value to development plans. This collaboration demonstrates the practical benefits of AI-driven analytics in clinical settings.
About PhaseV
PhaseV delivers AI and machine learning solutions to optimize clinical development. Their platform enables biopharma sponsors and CROs to design adaptive, Bayesian, and fixed clinical trials efficiently, analyze data to uncover treatment heterogeneity, stratify patients, and guide R&D decisions.
By helping reduce trial costs, shorten trial durations, and improve success probabilities, PhaseV supports over 30 major pharmaceutical and biotech clients across multiple therapeutic areas.
For professionals interested in AI applications in healthcare and clinical development, exploring advanced training options can provide valuable insights. Check out Complete AI Training for courses tailored to AI development and implementation.
Your membership also unlocks:
